Western Blot (WB)
(Western blot analysis of anti-KDR/FLK1 Pab in HeLa cell lysate. KDR (VEGFR2) (arrow) was detected using purified Pab. Secondary HRP-anti-rabbit was used for signal visualization with chemiluminescence.)
Rabbit anti-Human VEGFR2 (FLK1/KDR) Polyclonal Antibody | anti-KDR antibody
VEGFR2 (FLK1/KDR) Antibody (C-term)
Western Blot (WB)
(Western blot analysis of anti-KDR/FLK1 Pab in HeLa cell lysate. KDR (VEGFR2) (arrow) was detected using purified Pab. Secondary HRP-anti-rabbit was used for signal visualization with chemiluminescence.)
Western Blot (WB)
(Western blot analysis of anti-KDR/FLK1 Pab in HeLa cell lysate. KDR (VEGFR2) (arrow) was detected using purified Pab. Secondary HRP-anti-rabbit was used for signal visualization with chemiluminescence.)
Immunofluorescence (IF)
(Confocal immunofluorescent analysis of VEGFR2 (FLK1/KDR) Antibody (C-term) with Hela cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green).DAPI was used to stain the cell nuclear (blue).)
Immunofluorescence (IF)
(Confocal immunofluorescent analysis of VEGFR2 (FLK1/KDR) Antibody (C-term) with Hela cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green).DAPI was used to stain the cell nuclear (blue).)
Flow Cytometry (FC/FACS)
(VEGFR2 (FLK1/KDR) Antibody (C-term) flow cytometric analysis of MDA-MB435 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.)
Flow Cytometry (FC/FACS)
(VEGFR2 (FLK1/KDR) Antibody (C-term) flow cytometric analysis of MDA-MB435 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.)
Immunohistochemistry (IHC)
(Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
Immunohistochemistry (IHC)
(Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
Function: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.
Zeng, H., et al., J. Biol. Chem. 278(23):20738-20745 (2003).
Kiba, A., et al., J. Biol. Chem. 278(15):13453-13461 (2003).
Elvert, G., et al., J. Biol. Chem. 278(9):7520-7530 (2003).
Yang, S., et al., Arterioscler. Thromb. Vasc. Biol. 22(11):1797-1803 (2002).
NCBI and Uniprot Product Information
NCBI Description
Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009]
Uniprot Description
VEGFR2: a receptor tyrosine kinase of the VEGFR family. High affinity receptor for VEGF and VEGF-C. Ligand binding induces autophosphorylation and activation. Activated receptor recruits proteins including Shc, GRB2, PI3K, Nck, SHP-1 and SHP-2. Plays a key role in vascular development and regulation of vascular permeability.
Protein type: Kinase, protein; Membrane protein, integral; Protein kinase, tyrosine (receptor); EC 2.7.10.1; Protein kinase, TK; TK group; VEGFR family
Chromosomal Location of Human Ortholog: 4q11-q12
Cellular Component: Golgi apparatus; integral to plasma membrane; endoplasmic reticulum; early endosome; cytoplasmic membrane-bound vesicle; extracellular region; plasma membrane; nucleus; cell junction; endosome; external side of plasma membrane; lipid raft
Molecular Function: integrin binding; vascular endothelial growth factor receptor activity; protein binding; growth factor binding; protein-tyrosine kinase activity; Hsp90 protein binding; transmembrane receptor protein tyrosine kinase activity; receptor signaling protein tyrosine kinase activity; ATP binding
Biological Process: extracellular matrix organization and biogenesis; positive regulation of positive chemotaxis; peptidyl-tyrosine phosphorylation; viral reproduction; protein amino acid autophosphorylation; cell maturation; calcium ion homeostasis; regulation of cell shape; ovarian follicle development; positive regulation of MAPKKK cascade; positive regulation of focal adhesion formation; positive regulation of mesenchymal cell proliferation; positive regulation of cell proliferation; angiogenesis; vasculogenesis; endothelial cell differentiation; cell fate commitment; embryonic hemopoiesis; positive regulation of phosphoinositide 3-kinase cascade; positive regulation of angiogenesis; branching morphogenesis of a tube; cell migration during sprouting angiogenesis; positive regulation of endothelial cell proliferation; positive regulation of protein amino acid phosphorylation; lymph vessel development; vascular endothelial growth factor receptor signaling pathway; surfactant homeostasis; alveolus development; transmembrane receptor protein tyrosine kinase signaling pathway; positive regulation of cell migration; positive regulation of nitric-oxide synthase biosynthetic process; negative regulation of apoptosis
Disease: Hemangioma, Capillary Infantile
Research Articles on KDR
Similar Products
Product Notes
The KDR kdr (Catalog #AAA9202213) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The immunogen sequence is 1326-1356. The VEGFR2 (FLK1/KDR) Antibody (C-term) reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's VEGFR2 (FLK1/KDR) can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), ELISA (EIA), Immunofluorescence (IF), Flow Cytometry (FC/FACS), Immunohistochemistry (IHC). WB: 1:1000; IF: 1:10~50; FC: 1:10~50; IHC-P: 1:50~100. Researchers should empirically determine the suitability of the KDR kdr for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "VEGFR2 (FLK1/KDR), Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
